Heparin-induced thrombocytopenia in pediatrics

Area of Science:

• Pediatric Hematology
• Thrombosis and Hemostasis
• Pharmacology

Background:

• Heparin is crucial for preventing and treating thromboembolism in pediatric patients.
• Heparin therapy carries a risk of heparin-induced thrombocytopenia (HIT), particularly HIT type II.
• Limited data exists on HIT type II in pediatric populations compared to adults.

Purpose of the Study:

• To review existing literature on HIT type II in pediatric patients.
• To present a case of recurrent thrombosis and HIT type II without thrombocytopenia in a child.
• To highlight the incidence, risk factors, and management of HIT type II in neonates, children, and adolescents.

Main Methods:

• Literature review of pediatric HIT type II cases.
• Case report of a pediatric patient with thrombosis and HIT type II.
• Analysis of age-specific incidence and clinical presentation.

Main Results:

• HIT type II predominantly affects neonates and adolescents, aligning with pediatric thrombosis peaks.
• Risk factors include hereditary predisposition, immobilization, and surgery.
• Severe complications, including life-threatening thromboembolism, were observed.
• Thrombocytopenia was absent in five reported cases.
• Heparin was often switched to danaparoid sodium or hirudin.

Conclusions:

• HIT type II is a significant and potentially dangerous complication of heparin use in pediatric patients.
• Clinicians must consider HIT type II in neonates, children, and adolescents receiving heparin.
• Early recognition and alternative anticoagulation are vital for managing HIT type II in this population.